Sorbitan tristrearate

Catalog Number	ACM26658195-1
CAS	26658-19-5
Structure
Synonyms	Span 65
Molecular Weight	963.54
Molecular Formula	C60H114O8
Melting Point	53 °C
Purity	95%+
Physical State	Solid

Knowledge & Learning Case Study Q&A

Vesicle Formation in Pluronic P123 and Sorbitan Tristearate (Span 65) Mixtures

Sakai T, et al. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2011, 389(1-3), 82-89.

Sorbitan tristearate (Span 65), a hydrophobic nonionic surfactant, demonstrates a unique ability to form vesicles when combined with the poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) block copolymer Pluronic P123 in aqueous solutions. The vesicles formed have diameters ranging from 4 to 30 μm and exhibit a ring-shaped structure, as confirmed by fluorescence microscopy. The internal aqueous phase within these vesicles was verified by measuring the entrapment efficiency of calcein using fluorescence spectroscopy.
The vesicles were prepared using a conventional chloroform film method. The mixture of Pluronic P123 and Span 65 was dissolved in chloroform, evaporated under vacuum, and the resulting dried film was hydrated with ultrapure water. This method allows for the formation of stable vesicular structures suitable for colloidal and biomedical applications. The findings highlight the importance of the hydrophobicity of nonionic surfactants like Span 65 in modulating the self-assembly behavior of block copolymers such as Pluronic P123.

Sorbitan Tristearate in Niosomal Formulations for Enhanced Drug Delivery

Hadjipour A, et al. Journal of Drug Delivery Science and Technology, 2024, 100, 106120.

Sorbitan tristearate (Span 65) has demonstrated significant potential in niosomal formulations for drug delivery, particularly in encapsulating both hydrophilic and hydrophobic drugs. Recent studies highlight the superior performance of Span 65 in encapsulating a combination of methylene blue (MB), a hydrophilic drug, and curcumin (CUR), a hydrophobic drug, within niosomes.
Vesicles were prepared using a thin film hydration technique. Briefly, 300 μmol of a stoichiometric mixture of Span 60 or Span 65, cholesterol, and Cremophor RH40 content was weighed, then dissolved in chloroform (12 mL) and transferred to a round-bottom flask. For formulations containing curcumin, accurately weighed curcumin (0.5 mg) was also added to the mixture at this stage. The solvent was evaporated under reduced pressure at 470 mbar, 100 rpm, and 60 °C using a rotary evaporator. Prior to the hydration step, the deposited film layer at the bottom of the flask was left in a fume hood for 30 min to ensure that there were no traces of solvent. At this point, 5 mL of Trizma buffer (pH 7.4) was added to hydrate the film. For formulations containing MB, MB was added after the addition of trizma buffer at this step. The round-bottom flask was placed in a water bath shaker and shaken at 150 rpm at 60 °C for 30 min and then allowed to stand in the dark for another 40 min.
The optimized formulation for dual drug entrapment was achieved with a molar ratio of Span 65:cholesterol
RH40 at 45:45:10, resulting in an entrapment efficiency (EE) of 91.19% for CUR alone, 51.70% for MB alone, and 45.32%/84.40% for combined MB/CUR-loaded formulations. This high EE, particularly for hydrophobic compounds like CUR, underscores Span 65's ability to expand the hydrophobic core of the niosome, thereby improving encapsulation capacity.

Our products and services are for research use only and cannot be used for any clinical purposes.

Online Inquiry

Sorbitan tristrearate (26658-19-5)

Send A Message